Have Your Say
Tweet your opinions @UKSPA
Doris-Ann Williams MBA,
Chief Executive, British
In Vitro Diagnostics
Association (BIVDA)
“Our focus at the AMRC has been to look
at solutions, to look at opportunities, to
be really clear about what’s at stake for
research and for patients and to speak our
truth no matter how difficult and possibly
how unpalatable that might be for some.”
Aisling Burnand,
Chief Executive, Association of Medical Research Charities
“Things are going to have to
change both in the way the
apprenticeship system works for
life sciences and also in terms of
how that money can be reinvested.
There needs to be much more
responsive mechanisms in place
between industry and higher
education establishments
to respond to the technology
changes that are driving the need
for different skills.”
Joanna Woolf,
Chief Executive, Cogent Skills
“It’s really
hard to
imagine how
we could
have a British
[regulatory]
system with
a lighter touch
but still fit
for purpose”
Doris-Ann Williams MBA, BIVDA
“It will be critical to avoid divergence
and duplication of regulatory regimes,
so that patient safety is not put at risk.”
r Virginia Acha, Executive Director, Research, Medicine & Innovation,
D
Association for the British Pharmaceutical Industry (ABPI), June 2017
S u m m er 2 0 17 | U K S PA breakthrough | 2 7
s
“Regulation on the
use of biocides, on
controlling animal
by-products and
ensuring they don’t
get into the food
chain, restriction
of hazardous
chemicals through
the REACH Directive,
all those sorts
of environmental
regulations have
got to be taken into
account. And
the reality is that we
will have to comply
with whatever
European regulation
exists post-Brexit,
so anything else is
just layering more
complexity on.”